View More Recent Stories
-
Stifel Reiterates Buy Rating on Mirum Pharamceuticals (MIRM)
-
Mirum Pharamceuticals (MIRM) PT Raised to $39 at Baird
-
Citi Reiterates Buy Rating on Mirum Pharamceuticals (MIRM)
-
Mirum Pharmaceuticals' (MIRM) Volixibat Achieves Positive Interim Analyses in VANTAGE PBC and VISTAS PSC Studies


